This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2014 by Sidney Kimmel Comprehensive Cancer Center.
Recruitment status was:  Active, not recruiting
Biocompatibles UK Ltd
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: February 4, 2009
Last updated: January 30, 2014
Last verified: January 2014
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially. The purpose of the study is to establish the safety and the effectiveness of the combination therapy. The investigators hypothesize that the combination of the two therapies will not result in greater toxicities to patients than that expected for either therapy given alone.

Condition Intervention Phase
Hepatocellular Carcinoma Hepatoma Drug: sorafenib Procedure: LC Bead-TACE Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Sorafenib Combined With Doxorubicin Eluting Bead-Transarterial Chemoembolization (LC Bead-TACE) for Patients With Hepatocellular Carcinoma

Resource links provided by NLM:

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • Safety will be assessed by grading toxicities reported at intervals throughout the study. Higher grade toxicities will be assessed for their degree of relatedness to the study treatment. [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Efficacy will be assessed by review of the imaging scans, by comparing baseline scans to follow-up scan (post treatment). We will measure the size and viability of the treated lesions. [ Time Frame: 3 years ]

Enrollment: 50
Study Start Date: February 2009
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: sorafenib and drug eluting beads
single arm
Drug: sorafenib
sorafenib: given 400 mg twice per day for as long as it is beneficial
Other Name: sorafenib (Nexavar)
Procedure: LC Bead-TACE

LC Beads loaded with doxorubicin

Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period

Other Name: LC Beads manufactured by Biocompatibles


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Unresectable hepatocellular carcinoma patients with liver-predominant disease as described in section 5.1, or patients with hepatocellular carcinoma who refuse surgery. No more than 30% of the cohort should have macrovascular invasion and/or asymptomatic extrahepatic disease. Multifocal HCC is acceptable, no diffuse HCC.
  2. Age > 18 years old
  3. ECOG performance status of 0-1
  4. Childs class of A or B (up to 7) (see Table 5.0)
  5. Adequate end-organ function as manifested by:

    • Absolute neutrophil count of > 1500/mm3 and platelets > 50,000/mm3
    • Creatinine ≤ 2.0
    • AST ALT < 5 x ULN
    • Total bilirubin of ≤ 3
    • Albumin > 2.0
    • INR < 2.0
    • Leukocyte count >3000 cells/mm3
  6. Amylase and lipase ≤ 1.5 the upper limit of normal
  7. Patients who have received previous hepatic surgery , RFA, PEI, or cryoablation are eligible if target lesion(s) have not been treated and local therapy completed > 6 weeks prior to entry.
  8. Left ventricular ejection fraction ≥ 45%
  9. Patients with asymptomatic HIV infection are not eligible
  10. Willingness of male and female subjects, who are not surgically sterile or post menopausal, to use reliable methods of birth control for the duration of the study and for 30 days after the last dose of study medication.
  11. Patient must have signed informed consent prior to registration on study.
  12. Resolution of all acute toxic effects of any prior local treatment to CTC adverse event Grade 1 or 0.
  13. At least one tumor lesion can be accurately measured in at least one dimension according to RECIST. The lesion has not been previously treated with local therapy (such as surgery, radiation therapy, RFA, PEI, or cryoablation) unless it has shown progression in the interim.

Exclusion Criteria:

  1. Patients unable to swallow oral medications
  2. Prior embolization, systemic or radiation therapy for HCC (liver)
  3. Tumor burden in the liver exceeding 70%.
  4. Complete occlusion of the entire portal venous system
  5. Ascites refractory to diuretic therapy (minimal or trace on imaging is acceptable)
  6. Previous or concurrent cancer that is distinct in primary site or histology from HCC, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1). Any cancer curatively treated > 3 years prior is permitted.
  7. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
  8. History of bleeding within the past 4 weeks (unless deemed by PI as clinically insignificant, for ex., a brief episode of epistaxis)
  9. Any contraindication to doxorubicin administration
  10. Evidence of severe or uncontrolled systemic diseases,
  11. Congestive cardiac failure >NYHA class 2, MI within 6 months, active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, unstable angina, or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial
  12. Any prior history of hypertensive crisis or hypertensive encephalopathy
  13. History of stroke or transient ischemic attack within 6 months prior to study enrollment
  14. Inadequately controlled hypertension (defined as systolic blood pressure of 150/100 mmHg on antihypertensive medications) (patients with treated hypertension are eligible)
  15. Significant vascular disease (e.g., aortic aneurysm, aortic dissection, peripheral vascular disease)
  16. History of organ allograft
  17. Presence of grade > 2 hepatic encephalopathy (see Appendix D)
  18. Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an additional experimental drug
  19. Evidence of bleeding diathesis or coagulopathy or on warfarin. Note: If a patient has been on coumadin for a period of 1 month and has been stable, they may be accepted into the protocol.
  20. Presence of clinically evident central nervous system or brain metastases
  21. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, anticipation of need for major surgical procedure during the course of the study
  22. Vascular anatomy that precludes catheter placement or injection of LC Bead microspheres
  23. Presence of collateral vessel pathways potentially endangering normal territories during embolization
  24. Pregnant (positive pregnancy test) or lactating
  25. Inability to comply with study and/or follow-up procedures
  26. Life expectancy of less than 12 weeks
  27. Child B8, B9 and C
  28. ECOG ≥ 2
  29. Patients with concomitant HIV infection or AIDS-related or serious acute or chronic illness
  30. Presence of porto-systemic shunt
  31. Severe atheromatosis
  32. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results
  33. Active clinically serious infections (>grade 2)
  34. Patients receiving therapy for hepatitis A, B, or C.
  35. Patients with obvious and/or symptomatic extrahepatic disease. Findings of uncertain significance, such as lung lesions less than 10 mm in diameter or enlarged periportal lymph nodes will not exclude patients, however, findings highly suspicious for metastatic HCC will exclude patients from this study.
  36. Any contraindication for an arterial procedure such as impaired clotting tests (platelet count < 50.000/mm3 or prothrombin activity < 50 percent)
  37. Any contraindication for systemic chemotherapy administration (serum bilirubin > 3mg/dL, leukocyte count < 3.000 cells/mm3)
  38. Any contraindication for sorafenib administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00844883

United States, Maryland
The Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
Biocompatibles UK Ltd
  More Information

Responsible Party: Sidney Kimmel Comprehensive Cancer Center Identifier: NCT00844883     History of Changes
Other Study ID Numbers: J08110
Study First Received: February 4, 2009
Last Updated: January 30, 2014

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
primary liver cancer
drug eluting beads
transarterial chemoembolization

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on August 22, 2017